TD Cowen Issues Positive Forecast for Puma Biotechnology (NASDAQ:PBYI) Stock Price

Puma Biotechnology (NASDAQ:PBYI) had its target price boosted by TD Cowen from $5.00 to $6.00 in a research report sent to investors on Friday,Benzinga reports. The firm currently has a hold rating on the biopharmaceutical company’s stock.

Several other brokerages have also recently commented on PBYI. Weiss Ratings cut Puma Biotechnology from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Wall Street Zen lowered shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 16th. Two investment analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, Puma Biotechnology currently has an average rating of “Hold” and a consensus target price of $6.00.

Puma Biotechnology Trading Up 9.7%

NASDAQ:PBYI opened at $8.91 on Friday. The firm has a market cap of $453.52 million, a price-to-earnings ratio of 17.13 and a beta of 1.22. Puma Biotechnology has a twelve month low of $3.05 and a twelve month high of $9.40. The company has a 50-day moving average of $7.80 and a 200-day moving average of $7.18.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.15. The firm had revenue of $56.50 million for the quarter, compared to analyst estimates of $53.00 million. Puma Biotechnology had a net margin of 11.50% and a return on equity of 21.34%. On average, research analysts forecast that Puma Biotechnology will post 0.28 earnings per share for the current year.

Insider Transactions at Puma Biotechnology

In other Puma Biotechnology news, CEO Alan H. Auerbach sold 44,058 shares of the business’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $8.26, for a total value of $363,919.08. Following the sale, the chief executive officer owned 7,261,671 shares of the company’s stock, valued at $59,981,402.46. The trade was a 0.60% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jay M. Moyes sold 22,000 shares of the stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $7.22, for a total transaction of $158,840.00. Following the completion of the transaction, the director directly owned 58,322 shares of the company’s stock, valued at $421,084.84. This trade represents a 27.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 132,028 shares of company stock worth $1,006,711. 22.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Barclays PLC lifted its position in shares of Puma Biotechnology by 1.9% during the fourth quarter. Barclays PLC now owns 81,434 shares of the biopharmaceutical company’s stock worth $485,000 after purchasing an additional 1,553 shares in the last quarter. Cerity Partners LLC grew its stake in shares of Puma Biotechnology by 18.2% during the fourth quarter. Cerity Partners LLC now owns 12,072 shares of the biopharmaceutical company’s stock worth $72,000 after purchasing an additional 1,862 shares during the period. BNP Paribas Financial Markets increased its stake in Puma Biotechnology by 39.7% in the third quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 2,290 shares in the last quarter. Kathmere Capital Management LLC increased its holdings in shares of Puma Biotechnology by 9.8% in the first quarter. Kathmere Capital Management LLC now owns 29,779 shares of the biopharmaceutical company’s stock worth $190,000 after acquiring an additional 2,648 shares in the last quarter. Finally, Baron Wealth Management LLC increased its position in shares of Puma Biotechnology by 8.2% during the first quarter. Baron Wealth Management LLC now owns 38,278 shares of the biopharmaceutical company’s stock worth $245,000 after acquiring an additional 2,886 shares in the last quarter. Institutional investors own 61.29% of the company’s stock.

Puma Biotechnology News Roundup

Here are the key news stories impacting Puma Biotechnology this week:

• Positive Sentiment: Second-quarter results exceeded expectations. Puma reported earnings of $0.19 per share, above the $0.04 consensus estimate, while revenue reached $56.5 million versus expectations of $53.0 million. Profitability included a 10.69% net margin and 20.30% return on equity. Puma Biotechnology Q2 2026 earnings results
• Positive Sentiment: Full-year 2026 revenue guidance was raised. Puma now expects revenue of $224 million to $231 million, above the approximately $222.5 million analyst consensus. Rising Nerlynx sales and planned milestones for the alisertib program provide additional potential catalysts. PBYI Q2 earnings and raised guidance
• Neutral Sentiment: Management’s outlook was mixed for the next quarter. Third-quarter revenue guidance of $56 million to $59 million is slightly below the $59.4 million consensus estimate, suggesting that near-term growth may be more modest despite the improved full-year outlook. Puma Biotech Q2 earnings and revenue results
• Negative Sentiment: TD Cowen remains cautious. The firm raised its price target from $5 to $6 but maintained a “hold” rating. The revised target still implies roughly 32.7% downside from the referenced $8.91 share price, potentially weighing on investor sentiment after the recent advance. TD Cowen raises Puma Biotechnology price target

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.